Lymphoblastic Leukemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LYM026 MIFTS: 66	Lymphoblastic Leukemia Categories: Cancer diseases, Rare diseases, Blood diseases, Genetic diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Lymphoblastic Leukemia

MalaCards integrated aliases for Lymphoblastic Leukemia:

Name: Lymphoblastic Leukemia ¹² ¹⁴

Precursor Cell Lymphoblastic Leukemia Lymphoma ⁶⁹

Acute Lymphocytic Leukemia ⁶⁹

Leukemia, Lymphoid ⁴¹

Lymphoid Leukemia ⁶⁹

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases Genetic diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Lymphoid leukaemia

Lymphoid leukaemia, unspecified

External Ids:

Disease Ontology ¹² DOID:1037

ICD10 ³² C91 C91.9 C91.90

ICD9CM ³⁴ 204 204.9

MeSH ⁴¹ D007945

NCIt ⁴⁶ C7539

SNOMED-CT ⁶⁴ 154587007 188725004 188731001 more

UMLS ⁶⁹ C0023448 C1961102

Sources

Summaries for Lymphoblastic Leukemia

Disease Ontology : ¹² A leukemia that has material basis in lymphoblasts (immature white blood cells).

MalaCards based summary : Lymphoblastic Leukemia, also known as precursor cell lymphoblastic leukemia lymphoma, is related to b-cell childhood acute lymphoblastic leukemia and acute lymphoblastic leukemia, childhood, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Lymphoblastic Leukemia is FLT3 (Fms Related Tyrosine Kinase 3), and among its related pathways/superpathways are Pathways in cancer and NF-kappaB Signaling. The drugs Arranon and Blincyto have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Sources

Related Diseases for Lymphoblastic Leukemia

Diseases in the Lymphoblastic Leukemia family:

Leukemia, Acute Lymphoblastic	Leukemia, Acute Lymphoblastic 2
Leukemia, Acute Lymphoblastic 3

Diseases related to Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 475)

#	Related Disease	Score	Top Affiliating Genes
1	b-cell childhood acute lymphoblastic leukemia	34.4	IKZF1 RUNX1
2	acute lymphoblastic leukemia, childhood	34.3	ETV6 FLT3 RUNX1
3	precursor t-cell acute lymphoblastic leukemia	33.4	ABL1 BAX ETV6 FLT3 IKZF1 LMO2
4	leukemia, acute lymphoblastic	33.4	ABL1 AFF1 BAX ETV6 FLT3 NBN
5	acute lymphocytic leukemia	33.2	ETV6 NBN NOTCH1 PAX5 RUNX1 TAL2
6	b-cell adult acute lymphocytic leukemia	33.1	ABL1 IKZF1 PAX5 PBX1
7	leukemia, acute myeloid	32.6	ABL1 AFF1 ETV6 FLT3 RUNX1
8	leukemia, acute lymphoblastic 3	32.5	ABL1 AFF1 ETV6 FLT3 IKZF1 PAX5
9	lymphoid leukemia	32.3	ETV6 RUNX1
10	leukemia	32.1	ABL1 BAX ETV6 FLT3 LYL1 PBX1
11	myeloid leukemia	31.1	ABL1 ETV6 FLT3 RUNX1
12	childhood leukemia	31.0	ABL1 ETV6 PBX1 RUNX1 TCF3
13	leukemia, chronic myeloid	30.9	ABL1 ETV6 FLT3 RUNX1
14	acute leukemia	30.9	AFF1 ETV6 FLT3 PAX5 RUNX1 TCF3
15	chronic myelomonocytic leukemia	30.6	ETV6 FLT3 RUNX1
16	myelodysplastic syndrome	30.6	ABL1 ETV6 FLT3 RUNX1
17	acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)	30.3	ETV6 FLT3 RUNX1
18	t-cell leukemia	29.8	LMO2 NOTCH1 TLX1
19	lymphoblastic leukemia, acute, with lymphomatous features	12.2
20	acute non lymphoblastic leukemia	12.2
21	acute lymphoblastic leukemia congenital sporadic aniridia	12.0
22	lymphoblastic lymphoma	11.9
23	precursor lymphoblastic lymphoma/leukemia	11.7
24	t-cell childhood acute lymphocytic leukemia	11.6
25	bone marrow necrosis	11.4
26	leukemia, chronic lymphocytic	11.4
27	precursor b lymphoblastic lymphoma/leukemia	11.4
28	acute t cell leukemia	11.3
29	t-cell adult acute lymphocytic leukemia	11.2
30	null-cell leukemia	11.2
31	medulloblastoma	11.0
32	precursor t-lymphoblastic lymphoma/leukemia	11.0
33	childhood precursor t-lymphoblastic lymphoma/leukemia	11.0
34	lymphoma	10.7
35	acute myeloid leukemia with t(8;21)(q22;q22) translocation	10.6	FLT3 RUNX1
36	platelet disorder, familial, with associated myeloid malignancy	10.6	ETV6 RUNX1
37	mn1	10.5	ETV6 FLT3
38	bone marrow cancer	10.5	ABL1 ETV6 FLT3 RUNX1
39	glucocorticoid resistance, generalized	10.3
40	prostate cancer	10.3
41	hematopoietic stem cell transplantation	10.3
42	hematologic cancer	10.2	ABL1 ETV6 FLT3 IKZF1 NOTCH1 PAX5
43	aging	10.2
44	hypercalcemia, infantile, 1	10.2
45	sarcoma	10.2
46	down syndrome	10.1
47	hereditary wilms' tumor	10.1
48	complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy	10.1
49	wilms tumor 6	10.1
50	osteonecrosis	10.1

Comorbidity relations with Lymphoblastic Leukemia via Phenotypic Disease Network (PDN):

Deficiency Anemia	Leukemia, Chronic Lymphocytic
Neutropenia

Graphical network of the top 20 diseases related to Lymphoblastic Leukemia:

Sources

Symptoms & Phenotypes for Lymphoblastic Leukemia

UMLS symptoms related to Lymphoblastic Leukemia:

edema, chest pain, angina pectoris

GenomeRNAi Phenotypes related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability in esophageal squamous lineage	GR00235-A	9.32	ABL1 AFF1 AFF4 BCL9 FLT3 LMO2

MGI Mouse Phenotypes related to Lymphoblastic Leukemia:

⁴³ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.4	ABL1 AFF4 BAX ETV6 FLT3 IKZF1
2	hematopoietic system	MP:0005397	10.39	ABL1 AFF1 AFF4 BAX ETV6 FLT3
3	growth/size/body region	MP:0005378	10.38	ABL1 AFF1 AFF4 BAX ETV6 FLT3
4	immune system	MP:0005387	10.31	RUNX1 TCF3 TLX1 PAX5 PBX1 ABL1
5	endocrine/exocrine gland	MP:0005379	10.27	ABL1 AFF1 AFF4 BAX ETV6 FLT3
6	mortality/aging	MP:0010768	10.27	RUNX1 TAL2 TCF3 ABL1 AFF1 AFF4
7	behavior/neurological	MP:0005386	10.24	OLIG2 PAX5 PBX1 RUNX1 TAL2 ABL1
8	embryo	MP:0005380	10.21	ABL1 AFF4 ETV6 LMO2 NBN NOTCH1
9	nervous system	MP:0003631	10.07	ABL1 AFF1 BAX LMO2 NBN NOTCH1
10	neoplasm	MP:0002006	10.06	RUNX1 TCF3 BAX ETV6 FLT3 IKZF1
11	liver/biliary system	MP:0005370	9.95	ABL1 IKZF1 LMO2 NOTCH1 PBX1 RUNX1
12	no phenotypic analysis	MP:0003012	9.7	AFF1 ETV6 FLT3 IKZF1 OLIG2 RUNX1
13	respiratory system	MP:0005388	9.56	RUNX1 ABL1 AFF4 BAX IKZF1 NOTCH1
14	skeleton	MP:0005390	9.28	ABL1 BAX FLT3 LMO2 NOTCH1 OLIG2

Sources

Drugs & Therapeutics for Lymphoblastic Leukemia

FDA approved drugs:

(show all 7)

#	Drug Name	Active Ingredient(s) ¹⁷	Company	Approval Date
1	Arranon ¹⁷ ⁴⁵	NELARABINE	GlaxoSmithKline	October 2005
FDA Label: Arranon Disease/s that Drug Treats:Lymphoblastic Leukemia Indications and Usage: ¹⁷ ARRANON is a nucleoside metabolic inhibitor indicated for the treatment ofpatients with T-cell acute lymphoblastic leukemia and T-cell lymphoblasticlymphoma whose disease has not responded to or has relapsed followingtreatment with at least two chemotherapy regimens. This use is based on theinduction of complete responses. Randomized trials demonstrating increasedsurvival or other clinical benefit have not been conducted. (1) DrugBank Targets: ¹⁵ DNA Mechanism of Action: ¹⁷ Target: DNA synthesis Action: disruptor --> apoptosis FDA: Nelarabine is a pro-drug of the deoxyguanosine analogue 9-Î²-D-arabinofuranosylguanine266 (ara-G), a nucleoside metabolic inhibitor. Nelarabine is demethylated by adenosine deaminase267 (ADA) to ara-G, mono-phosphorylated by deoxyguanosine kinase and deoxycytidine kinase, and268 subsequently converted to the active 5â-triphosphate, ara-GTP. Accumulation of ara-GTP in269 leukemic blasts allows for incorporation into deoxyribonucleic acid (DNA), leading to inhibition270 of DNA synthesis and cell death. Other mechanisms may contribute to the cytotoxic and271 systemic toxicity of nelarabine.
2	Blincyto ¹⁷ ⁴⁵	BLINATUMOMAB	Amgen	December 2014
FDA Label: Blincyto Disease/s that Drug Treats:Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia Indications and Usage: ¹⁷ BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated forthe treatment of Philadelphia chromosome-negative relapsed or refractory Bcellprecursor acute lymphoblastic leukemia (ALL). This indication isapproved under accelerated approval. Continued approval for this indicationmay be contingent upon verification of clinical benefit in subsequent trials. (1) DrugBank Targets: ¹⁵ 1. B-lymphocyte antigen CD19;2. T-cell surface glycoprotein CD3 delta chain Mechanism of Action: ¹⁷ Target: CD19-directed CD3 T-cell Action: engager FDA: Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on thesurface of cells of B-lineage origin and CD3 expressed on the surface of T cells. It activates endogenousT cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant Bcells. Blinatumomab mediates the formation of a synapse between the T cell and the tumor cell,upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatorycytokines, and proliferation of T cells, which result in redirected lysis of CD19+ cells.
3	Clolar ¹⁷ ⁴⁵	CLOFARABINE	Genzyme	December, 2004
FDA Label: Clolar Disease/s that Drug Treats:Lymphoblastic Leukemia Indications and Usage: ¹⁷ Clolar (clofarabine) injection is a purine nucleoside metabolic inhibitorindicated for the treatment of pediatric patients 1 to 21 years old with relapsedor refractory acute lymphoblastic leukemia after at least two prior regimens.This indication is based upon response rate. There are no trials verifying animprovement in disease-related symptoms or increased survival with Clolar.(1) DrugBank Targets: ¹⁵ 1. DNA polymerase alpha catalytic subunit;2. Ribonucleoside-diphosphate reductase large subunit;3. DNA Mechanism of Action: ¹⁷ Target: ribonucleotide reductase Action: inhibitor FDA: Clofarabine is sequentially metabolized intracellularly to the 5â-monophosphate metabolite bydeoxycytidine kinase and mono- and di-phospho-kinases to the active 5â-triphosphate metabolite.Clofarabine has affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equalto or greater than that of the natural substrate, deoxycytidine. Clofarabine inhibits DNA synthesisby decreasing cellular deoxynucleotide triphosphate pools through an inhibitory action onribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair throughincorporation into the DNA chain by competitive inhibition of DNA polymerases. The affinity ofclofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosinetriphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNArepair by incorporation into the DNA chain during the repair process. Clofarabine 5â-triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of thepro-apoptotic mitochondrial proteins, cytochrome C and apoptosis-inducing factor, leading toprogrammed cell death.Clofarabine is cytotoxic to rapidly proliferating and quiescent cancer cell types in vitro.
4	Erwinaze ¹⁷ ⁴⁵	asparaginase Erwinia chrysanthemi	Eusa Pharma	November of 2011
FDA Label: Erwinaze Disease/s that Drug Treats:acute lymphoblastic leukemia Indications and Usage: ¹⁷ ERWINAZE (asparaginase Erwinia chrysanthemi) is an asparagine specificenzyme indicated as a component of a multi-agent chemotherapeutic regimenfor the treatment of patients with acute lymphoblastic leukemia (ALL) whohave developed hypersensitivity to E. coli-derived asparaginase. (1) DrugBank Targets: - Mechanism of Action: ¹⁷ Target: deamidation of asparagine to aspartic acid and ammonia Action: catalyzer FDA: Asparaginase Erwinia chrysanthemi catalyzes the deamidation of asparagine to aspartic acid and ammonia, resultingin a reduction in circulating levels of asparagine. The mechanism of action of ERWINAZE is thought to be based onthe inability of leukemic cells to synthesize asparagine due to lack of asparagine synthetase activity, resulting incytotoxicity specific for leukemic cells that depend on an exogenous source of amino acid asparagine for theirprotein metabolism and survival.
5	Iclusig ¹⁷ ⁴⁵	PONATINIB HYDROCHLORIDE	Ariad Pharmaceuticals	December 2012
FDA Label: Iclusig Disease/s that Drug Treats:chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia Indications and Usage: ¹⁷ Iclusig is a kinase inhibitor indicated for the: Treatment of adult patients with T315I-positive chronic myeloidleukemia (chronic phase, accelerated phase, or blast phase) or T315IpositivePhiladelphia chromosome positive acute lymphoblasticleukemia (Ph+ ALL). Treatment of adult patients with chronic phase, accelerated phase, orblast phase chronic myeloid leukemia or Ph+ ALL for whom no othertyrosine kinase inhibitor (TKI) therapy is indicated. (1)These indications are based upon response rate. There are no trials verifying animprovement in disease-related symptoms or increased survival with Iclusig. DrugBank Targets: ¹⁵ 1. Tyrosine-protein kinase ABL1;2. Breakpoint cluster region protein;3. Mast/stem cell growth factor receptor Kit;4. Proto-oncogene tyrosine-protein kinase receptor Ret;5. Angiopoietin-1 receptor;6. Receptor-type tyrosine-protein kinase FLT3;7. Fibroblast growth factor receptor 1;8. Fibroblast growth factor receptor 2;9. Fibroblast growth factor receptor 3;10. Fibroblast growth factor receptor 4;11. Tyrosine-protein kinase Lck;12. Proto-oncogene tyrosine-protein kinase Src;13. Tyrosine-protein kinase Lyn;14. Vascular endothelial growth factor receptor 2;15. Platelet-derived growth factor receptor alpha Mechanism of Action: ¹⁷ Target: tyrosine kinase activity of ABL and T315I mutant ABL Action: inhibitor FDA: Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL withIC50 concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC50concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRCfamilies of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native ormutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native orT315I mutant BCR-ABL when compared to controls.
6	Marqibo ¹⁷ ⁴⁵	VINCRISTINE SULFATE	Talon Therapeutics	August 2012
FDA Label: Marqibo Disease/s that Drug Treats:Ph- acute lymphoblastic leukemia Indications and Usage: ¹⁷ Marqibo is a vinca alkaloid indicated for the treatment of adult patients withPhiladelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)in second or greater relapse or whose disease has progressed following two ormore anti-leukemia therapies. This indication is based on overall responserate. Clinical benefit such as improvement in overall survival has not beenverified (1.1). DrugBank Targets: ¹⁵ 1. Tubulin beta chain;2. Tubulin alpha-4A chain Mechanism of Action: ¹⁷ Target: tubulin Action: alters polymerization equilibrium FDA: Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate.Non-liposomal vincristine sulfate binds to tubulin, altering the tubulin polymerization equilibrium, resulting inaltered microtubule structure and function. Non-liposomal vincristine sulfate stabilizes the spindle apparatus,preventing chromosome segregation, triggering metaphase arrest and inhibition of mitosis.
7	Sprycel ¹⁷ ⁴⁵	DASATINIB	Bristol-Myers Squibb	June 2006
FDA Label: Sprycel Disease/s that Drug Treats:Chronic Myeloid Leukemia Indications and Usage: ¹⁷ SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+)chronic myeloid leukemia (CML) in chronic phase. (1, 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML with resistance or intolerance to prior therapy including imatinib. (1,14) adults with Philadelphia chromosome-positive acute lymphoblasticleukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14) DrugBank Targets: ¹⁵ 1. Tyrosine-protein kinase ABL1;2. Proto-oncogene tyrosine-protein kinase Src;3. Ephrin type-A receptor 2;4. Tyrosine-protein kinase Lck;5. Tyrosine-protein kinase Yes;6. Mast/stem cell growth factor receptor Kit;7. Platelet-derived growth factor receptor beta;8. Signal transducer and activator of transcription 5B;9. Abelson tyrosine-protein kinase 2;10. Tyrosine-protein kinase Fyn Mechanism of Action: ¹⁷ Target: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRÎ² kinases Action: inhibitor FDA: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRÎ². Based on modeling studies, dasatinib ispredicted to bind to multiple conformations of the ABL kinase.In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylatesensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia(CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under theconditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCRABLkinase domain mutations, activation of alternate signaling pathways involving the SRCfamily kinases (LYN, HCK), and multi-drug resistance gene overexpression.

Drugs for Lymphoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 689)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dasatinib

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

302962-49-8

3062316

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

50-02-2

5743

Methotrexate

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

1959-05-2, 59-05-2

126941

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

53-03-2

5865

Asparaginase

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

9015-68-3

Cytarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

147-94-4

6253

Daunorubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

20830-81-3

30323

Idarubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

58957-92-9

42890

Vincristine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

2068-78-2, 57-22-7

5978

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

50-18-0, 6055-19-2

2907

Doxorubicin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

23214-92-8

31703

Pegaspargase

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

130167-69-0

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

135968-09-1

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

83-43-2

6741

Prednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

50-24-8

5755

rituximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

174722-31-7

10201696

Cladribine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

4291-63-8

20279

Etoposide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

33419-42-0

36462

Fludarabine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

21679-14-1, 75607-67-9

30751

Teniposide

Approved

Phase 4,Phase 3,Phase 2

29767-20-2

34698

Thioguanine

Approved

Phase 4,Phase 3,Phase 2,Phase 1

154-42-7

2723601

Vindesine

Approved, Investigational

Phase 4,Phase 3,Phase 2

53643-48-4, 59917-39-4

40839

Adenosine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

58-61-7

60961

Pentostatin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

53910-25-1

439693 40926

Ifosfamide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

3778-73-2

3690

Hydrocortisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

50-23-7

657311 5754

Mitoxantrone

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

65271-80-9

4212

Chlorambucil

Approved

Phase 4,Phase 3,Phase 2,Phase 1

305-03-3

2708

Vidarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

24356-66-9

21704 32326

Thiotepa

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

52-24-4

5453

Busulfan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

55-98-1

2478

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

22916-47-8

4189

Valganciclovir

Approved, Investigational

Phase 4,Phase 2

175865-60-8

64147

Dopamine

Approved

Phase 4

51-61-6, 62-31-7

681

Methylphenidate

Approved, Investigational

Phase 4

20748-11-2, 113-45-1

4158

Oprelvekin

Approved, Investigational

Phase 4

145941-26-0

Menthol

Approved

Phase 4

2216-51-5

16666

Micafungin

Approved, Investigational

Phase 4,Phase 2

235114-32-6

477468 3081921

Posaconazole

Approved, Investigational, Vet_approved

Phase 4

171228-49-2

147912

Amphotericin B

Approved, Investigational

Phase 4,Phase 3,Phase 2

1397-89-3

5280965 14956

Nicotine

Approved

Phase 4

54-11-5

89594 942

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

59-30-3

6037

leucovorin

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

58-05-9

143 6006

Cholecalciferol

Approved, Nutraceutical

Phase 4,Phase 3,Early Phase 1

67-97-0

10883523 5280795 6221

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 3,Phase 2,Early Phase 1

1406-16-2

Ergocalciferol

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2,Early Phase 1

50-14-6

5280793

Doxil

Approved June 1999

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

31703

Butyric Acid

Experimental, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

107-92-6

264

Treosulfan

Investigational

Phase 4,Phase 3,Phase 2,Phase 1

299-75-2

9296

Antiemetics

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2673)

#	Name	Status	NCT ID	Phase	Drugs
1	Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients	Unknown status	NCT02690922	Phase 4	Dasatinib;prednisone;dexamethasone;methotrexate
2	Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia	Unknown status	NCT01990807	Phase 4	Idarubicin(IDA)
3	Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003	Unknown status	NCT00222612	Phase 4	Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
4	German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Unknown status	NCT00198978	Phase 4	Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
5	Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses	Unknown status	NCT00192673	Phase 4	PEG-asparaginase
6	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)	Unknown status	NCT00198991	Phase 4	Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
7	HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL	Unknown status	NCT01873807	Phase 4	IDA;CTX;VP-16
8	Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.	Unknown status	NCT00131313	Phase 4	Nipent, Cytoxan, Rituxan
9	Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults	Unknown status	NCT00797810	Phase 4	Rituximab
10	ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors	Unknown status	NCT02290132	Phase 4	Rabbit Anti－human Thymocyte Globulin (ATG)
11	Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission	Unknown status	NCT01901666	Phase 4	Growth Hormone
12	Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia	Completed	NCT00411541	Phase 4	vincristine;dexamethasone
13	Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia	Completed	NCT01358253	Phase 4	Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
14	LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia	Completed	NCT00526409	Phase 4	Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
15	PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia	Completed	NCT00494897	Phase 4	Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
16	LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive	Completed	NCT00526305	Phase 4	Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
17	Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia	Completed	NCT00199095	Phase 4	Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
18	ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia	Completed	NCT00114348	Phase 4
19	Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America	Completed	NCT02559583	Phase 4
20	A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)	Completed	NCT01056510	Phase 4	bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
21	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)	Completed	NCT00199069	Phase 4	Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
22	Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab	Completed	NCT00199004	Phase 4	Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
23	Antiviral Treatment of Chronic Lymphocytic Leukemia	Completed	NCT01255644	Phase 4	Valganciclovir
24	A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status	Completed	NCT01271010	Phase 4	Cyclophosphamide;Fludarabine;Rituximab
25	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)	Completed	NCT00199056	Phase 4	Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
26	A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status	Completed	NCT01283386	Phase 4	chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
27	Learning Impairments Among Survivors of Childhood Cancer	Completed	NCT00576472	Phase 4	Methylphenidate
28	LAL-BR/2001: Study Treatment to Low Risk ALL	Completed	NCT00526175	Phase 4	Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
29	A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia	Completed	NCT00220311	Phase 4	Fludarabine Phosphate (Fludara)
30	Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)	Completed	NCT00802737	Phase 4	Ofatumumab
31	Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL	Completed	NCT02314273	Phase 4	rhIL-11
32	The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL	Completed	NCT00919321	Phase 4
33	Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults	Completed	NCT00199082	Phase 4	Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
34	Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy	Completed	NCT00524407	Phase 4	Epoetin alfa
35	The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents	Completed	NCT02953730	Phase 4	PEG-rhG-CSF
36	German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults	Completed	NCT00199017	Phase 4	Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
37	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
38	Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia	Recruiting	NCT02618109	Phase 4
39	Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)	Recruiting	NCT01366898	Phase 4	Dexamethasona, Idarubicine, ARA-C, Methotrexate
40	The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia	Recruiting	NCT00846703	Phase 4	6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
41	Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study	Recruiting	NCT02894645	Phase 4	Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
42	Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE	Recruiting	NCT01491763	Phase 4	Imatinib
43	Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid	Recruiting	NCT01906671	Phase 4	Xaluprine;Puri-Nethol
44	PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years	Recruiting	NCT01358201	Phase 4	vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
45	Vaccinating Children After Chemotherapy	Recruiting	NCT02447718	Phase 4
46	ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)	Recruiting	NCT02670564	Phase 4
47	Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia	Recruiting	NCT02036489	Phase 4	Vincristine;Daunorubicin;Prednisone;L-asparaginase;Ciclophosphamide;Metotrexate;ARA-C;Hidrocortisone;Mercaptopurine;VP-16;Dexametasone
48	Low Grade Lymphoma	Recruiting	NCT01698866	Phase 4
49	ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors	Recruiting	NCT02938741	Phase 4	Anti－human Thymoglobulin;Placebo
50	Rituximab (RTX) Therapy in Patients With Active TAO	Recruiting	NCT02378298	Phase 4	Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate

Search NIH Clinical Center for Lymphoblastic Leukemia

Inferred drug relations via UMLS ⁶⁹ / NDF-RT ⁴⁷ :

asparaginase

bendamustine

clofarabine

cyclophosphamide

dasatinib

idarubicin

idarubicin hydrochloride

ifosfamide

imatinib

imatinib mesylate

mercaptopurine

pegaspargase

sargramostim

teniposide

Cochrane evidence based reviews: leukemia, lymphoid

Sources

Genetic Tests for Lymphoblastic Leukemia

Sources

Anatomical Context for Lymphoblastic Leukemia

MalaCards organs/tissues related to Lymphoblastic Leukemia:

³⁸

B Cells, T Cells, Bone, Bone Marrow, Myeloid, Kidney, Nk Cells

Sources

Publications for Lymphoblastic Leukemia

Articles related to Lymphoblastic Leukemia:

(show top 50) (show all 3469)

#	Title	Authors	Year
1	<i>PDGFRB</i> mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. ( 29434033 )	Zhang Y....Liu X.	2018
2	Immunosuppressive monocytes (CD14<sup>+</sup>/HLA-DR<sup>low/-</sup>) increase in childhood precursor B-cell acute lymphoblastic leukemia after induction chemotherapy. ( 29429058 )	Lima D.S....Matos D.M.	2018
3	Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice. ( 29441205 )	Xie V....Bendall L.J.	2018
4	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. ( 29090524 )	Rau R.E....Hunger S.P.	2018
5	Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. ( 29047158 )	Abaza Y....Ravandi F.	2018
6	Flow cytometric characterization of acute leukemia reveals a distinctive "blast gate" of murine T-lymphoblastic leukemia/lymphoma. ( 29416774 )	Pan Z....Li Z.	2018
7	Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. ( 29449437 )	Sinclair P.B....Harrison C.J.	2018
8	MicroRNA expression and activity in T-cell acute lymphoblastic leukemia. ( 29435192 )	Ye F.	2018
9	A strategy for the clinical remission of acute lymphoblastic leukemia elicited by treatment of I^-thalassemia major: A case report. ( 29435306 )	Palomo-Colli M.A....CA^rdova-Hurtado L.P.	2018
10	Long non-coding RNA PAX8-AS1 polymorphisms increase the risk of childhood acute lymphoblastic leukemia. ( 29435279 )	Bahari G....Taheri M.	2018
11	Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate. ( 29424258 )	ZajA8c-SpychaA8a O....Wachowiak J.	2018
12	A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia. ( 29424254 )	Derrieux C....Fouillard L.	2018
13	Erratum: Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]. ( 29443320 )		2018
14	Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia. ( 28853218 )	Liang D.C....Shih L.Y.	2018
15	Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia. ( 29446543 )	Agarwal M....Seth R.	2018
16	Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. ( 29360413 )	Sakamoto K....Horibe K.	2018
17	T-Lymphoblastic Leukemia/Lymphoma With Annular Skin Rash and Epidermotropism. ( 29443697 )	Mansoori P....Sangueza O.P.	2018
18	Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL). ( 29437555 )	Yun S....Pinilla-Ibarz J.	2018
19	A rare e14a3 BCR/ABL fusion transcript in acute lymphoblastic leukemia patient treated with CAR-modified T-cell therapy. ( 29434963 )	Cai H....Xiao M.	2018
20	Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. ( 29450465 )	Siegel S.E....Bleyer A.	2018
21	Both left ventricular papillary muscles necrosis, an eosinophylic lymphoblastic leukemia revealed by endomyocardial fibrosis. ( 29366603 )	Dufour M....Cochet H.	2018
22	Recent Developments in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia. ( 29442287 )	Orellana-Noia V.M....Douvas M.G.	2018
23	Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults. ( 29418064 )	McNeer J.L....Bleyer A.	2018
24	MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. ( 29449434 )	Evensen N.A....Carroll W.L.	2018
25	Successful Combination Therapy of Liposomal Amphotericin B and Caspofungin for Disseminated Fusariosis in a Pediatric Patient with Acute Lymphoblastic Leukemia. ( 29438132 )	Uemura S....Kosaka Y.	2018
26	Lymphomatoid Granulomatosis in a 14-Year-Old Boy with Trisomy 21 and History of B-Lymphoblastic Leukemia/Lymphoma. ( 29336635 )	Matynia A.P....Li D.	2018
27	CREB knockdown inhibits growth and induces apoptosis in human pre-B acute lymphoblastic leukemia cells through inhibition of prosurvival signals. ( 28063408 )	Shabestari R.M....Kazemi A.	2017
28	Treatment of unilateral zone I cytomegalovirus retinitis in acute lymphoblastic leukemia with oral valganciclovir and intravitreal ganciclovir. ( 29118508 )	Tripathy K....Chawla R.	2017
29	The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia. ( 29023469 )	Choi S.H....Blacklow S.C.	2017
30	T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases. ( 27717083 )	Doerrenberg M....Hoell J.I.	2017
31	Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy. ( 28719513 )	Gervasini G....Vagace J.M.	2017
32	Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. ( 28461505 )	Schwartzman O....Izraeli S.	2017
33	Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia. ( 27637012 )	Dou H....Bao L.	2017
34	The Relationship Between MMP-2 -1306C>T and MMP-9 -1562C>T Polymorphisms and the Risk and Prognosis of T-Cell Acute Lymphoblastic Leukemia in a Chinese Population: A Case-Control Study. ( 28719899 )	Lin C.M....Yang T.	2017
35	Upregulation of microRNA-21 is a poor prognostic marker in patients with childhood B cell acute lymphoblastic leukemia. ( 28253825 )	Labib H.A....Alnagar A.A.	2017
36	Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. ( 28270453 )	Rahman S....Mansour M.R.	2017
37	Epigenetic targeting of Notch1 driven transcription using the HDACi panobinostat is a potential therapy against T cell acute lymphoblastic leukemia. ( 28914259 )	Waibel M....Johnstone R.W.	2017
38	Biomarker analysis and clinical relevance of TK1 on the cell membrane of Burkitt's lymphoma and acute lymphoblastic leukemia. ( 28919785 )	Weagel E.G....O'Neill K.L.	2017
39	Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia. ( 28923207 )	Barwe S.P....Gopalakrishnapillai A.	2017
40	Extramedullary Gastric Relapse at the Time of Bone Marrow Relapse of Acute Lymphoblastic Leukemia after Allogeneic Bone Marrow Transplantation. ( 28943549 )	Ikeuchi K....Ohashi K.	2017
41	ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. ( 27634205 )	Hirabayashi S....Kiyokawa N.	2017
42	Selected miRNA levels are associated with IKZF1 microdeletions in pediatric acute lymphoblastic leukemia. ( 28927157 )	Krzanowski J....Zawlik I.	2017
43	Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study. ( 28085747 )	Dujua A.C....Hernandez F.G.	2017
44	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. ( 28866095 )	Sadras T....White D.L.	2017
45	NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon. ( 27577869 )	Zgheib N.K....Muwakkit S.A.	2017
46	Oral mucositis and saliva IgA, IgG and IgM concentration during anti-tumor treatment in children suffering from acute lymphoblastic leukemia. ( 29442455 )	Pels E.J.	2017
47	Adult pre B-cell acute lymphoblastic leukemia with unusually large proportion of bone marrow CD45 bright/high SSc blasts. ( 26415521 )	Shahal-Zimra Y....Rabizadeh E.	2017
48	Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents. ( 28440015 )	Persson L....Ranta S.	2017
49	Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia. ( 28922466 )	Zhu M....Doshi S.	2017
50	Severe hypertriglyceridemia during treatment of acute lymphoblastic leukemia associated with type III hyperlipoproteinemia. ( 28371240 )	Yamada Y....Shimada H.	2017

Sources

Genes for Lymphoblastic Leukemia

Genes related to Lymphoblastic Leukemia (0 elite genes):

(show all 42)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Implication
1	FLT3	Fms Related Tyrosine Kinase 3	Protein Coding	56.21	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries Functions Variants (show sections)
2	LYL1	LYL1, Basic Helix-Loop-Helix Family Member	Protein Coding	55.64	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Gene name Summaries Transcripts (show sections)
3	RUNX1	Runt Related Transcription Factor 1	Protein Coding	47.3	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Functions (show sections)
4	TCF3	Transcription Factor 3	Protein Coding	46.07	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
5	PBX1	PBX Homeobox 1	Protein Coding	45.94	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
6	TAL2	TAL BHLH Transcription Factor 2	Protein Coding	42.51	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries Functions (show sections)
7	AFF4	AF4/FMR2 Family Member 4	Protein Coding	42.11	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
8	BCL9	B Cell CLL/Lymphoma 9	Protein Coding	41	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
9	ETV6	ETS Variant 6	Protein Coding	37.32	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
10	IKZF1	IKAROS Family Zinc Finger 1	Protein Coding	37.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
11	HMHB1	Histocompatibility Minor HB-1	Protein Coding	36.86	GeneCards inferred via : Publications Summaries Functions Expressions (show sections)
12	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	36.84	GeneCards inferred via : Publications Expressions Variants (show sections)
13	NOTCH1	Notch 1	Protein Coding	36.62	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
14	ABL1	ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase	Protein Coding	36.61	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
15	PAX5	Paired Box 5	Protein Coding	35.55	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
16	LMO2	LIM Domain Only 2	Protein Coding	35.1	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
17	NBN	Nibrin	Protein Coding	27.93	GeneCards inferred via : Disorders Publications Variants (show sections)
18	OLIG2	Oligodendrocyte Transcription Factor 2	Protein Coding	27.36	GeneCards inferred via : Disorders Publications Summaries (show sections)
19	AFF1	AF4/FMR2 Family Member 1	Protein Coding	26.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
20	TLX1	T Cell Leukemia Homeobox 1	Protein Coding	26.25	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
21	CRLF2	Cytokine Receptor Like Factor 2	Protein Coding	25.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
22	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	25.31	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
23	IL2	Interleukin 2	Protein Coding	25.25	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
24	ARID5B	AT-Rich Interaction Domain 5B	Protein Coding	24.94	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
25	TLX3	T Cell Leukemia Homeobox 3	Protein Coding	24.86	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
26	BCR	BCR, RhoGEF And GTPase Activating Protein	Protein Coding	24.81	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
27	ATM	ATM Serine/Threonine Kinase	Protein Coding	24.33	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
28	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	24.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Variants (show sections)
29	LMO1	LIM Domain Only 1	Protein Coding	23.86	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
30	JAK2	Janus Kinase 2	Protein Coding	23.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
31	LCK	LCK Proto-Oncogene, Src Family Tyrosine Kinase	Protein Coding	22.63	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
32	HLF	HLF, PAR BZIP Transcription Factor	Protein Coding	22.43	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
33	MLLT1	MLLT1, Super Elongation Complex Subunit	Protein Coding	22.3	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
34	NT5C2	5'-Nucleotidase, Cytosolic II	Protein Coding	22.17	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
35	CYP1A1	Cytochrome P450 Family 1 Subfamily A Member 1	Protein Coding	21.93	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
36	BLNK	B Cell Linker	Protein Coding	21.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
37	ABCC5	ATP Binding Cassette Subfamily C Member 5	Protein Coding	21.78	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
38	SLX4IP	SLX4 Interacting Protein	Protein Coding	21.73	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
39	MEF2D	Myocyte Enhancer Factor 2D	Protein Coding	21.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
40	PICALM	Phosphatidylinositol Binding Clathrin Assembly Protein	Protein Coding	21.42	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
41	TSPAN7	Tetraspanin 7	Protein Coding	21.42	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name (show sections)
42	AUTS2	AUTS2, Activator Of Transcription And Developmental Regulator	Protein Coding	21.36	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)

Sources

Variations for Lymphoblastic Leukemia

Sources

Expression for Lymphoblastic Leukemia

Search GEO for disease gene expression data for Lymphoblastic Leukemia.

Sources

Pathways for Lymphoblastic Leukemia

Pathways related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Pathways in cancer ³⁶	12.49	ABL1 BAX FLT3 NOTCH1 RUNX1
2	NF-kappaB Signaling ⁴	12.23	IKZF1 PAX5 PBX1 RUNX1 TCF3
3	Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶¹	11.68	LMO2 NOTCH1 RUNX1 TCF3
4	Transcriptional misregulation in cancer ³⁶	11.63	AFF1 BAX ETV6 FLT3 LMO2 LYL1
5	Hematopoietic Stem Cell Differentiation ¹	11.03	IKZF1 LMO2 LYL1 NOTCH1 RUNX1
6	Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex ¹	10.78	ETV6 FLT3
7	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶²	10.75	ABL1 BAX
8	Wnt/beta-catenin Signaling Pathway in Leukemia ¹	10.71	BCL9 FLT3 TCF3

Sources

GO Terms for Lymphoblastic Leukemia

Cellular components related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleoplasm	GO:0005654	9.7	ABL1 AFF4 BCL9 IKZF1 LMO2 NBN
2	nucleus	GO:0005634	9.6	ABL1 AFF1 AFF4 BAX BCL9 ETV6

Biological processes related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	transcription, DNA-templated	GO:0006351	9.9	AFF4 ETV6 IKZF1 LYL1 NOTCH1 OLIG2
2	transcription by RNA polymerase II	GO:0006366	9.88	AFF4 ETV6 PAX5 PBX1 RUNX1 TLX1
3	post-embryonic development	GO:0009791	9.71	ABL1 BAX TAL2
4	B cell differentiation	GO:0030183	9.69	FLT3 LYL1 TCF3
5	positive regulation of transcription by RNA polymerase II	GO:0045944	9.65	BCL9 ETV6 IKZF1 LMO2 NOTCH1 PAX5
6	negative regulation of neuron differentiation	GO:0045665	9.63	NOTCH1 OLIG2 PBX1
7	skeletal muscle cell differentiation	GO:0035914	9.61	BCL9 NOTCH1 PAX5
8	thalamus development	GO:0021794	9.56	OLIG2 TAL2
9	regulation of hematopoietic stem cell differentiation	GO:1902036	9.56	ABL1 LMO2 RUNX1 TCF3
10	hematopoietic stem cell proliferation	GO:0071425	9.55	ETV6 RUNX1
11	regulation of B cell receptor signaling pathway	GO:0050855	9.52	PAX5 RUNX1
12	positive regulation of interferon-gamma secretion	GO:1902715	9.48	ABL1 HMHB1
13	regulation of transcription, DNA-templated	GO:0006355	9.47	ABL1 AFF1 AFF4 ETV6 IKZF1 LYL1
14	leukocyte homeostasis	GO:0001776	9.37	BAX FLT3
15	apoptotic process involved in embryonic digit morphogenesis	GO:1902263	9.32	BAX NOTCH1
16	cell differentiation	GO:0030154	10.04	ETV6 FLT3 NOTCH1 PAX5 PBX1 TCF3
17	multicellular organism development	GO:0007275	10.04	IKZF1 LMO2 NOTCH1 OLIG2 PAX5 PBX1

Molecular functions related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA binding	GO:0003677	9.9	ABL1 ETV6 IKZF1 LYL1 OLIG2 PAX5
2	transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0001077	9.73	ETV6 PAX5 PBX1 TLX1
3	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.72	ETV6 PAX5 PBX1 TCF3 TLX1
4	protein dimerization activity	GO:0046983	9.71	LYL1 OLIG2 TAL2 TCF3
5	RNA polymerase II transcription factor activity, sequence-specific DNA binding	GO:0000981	9.67	ETV6 LMO2 LYL1 TAL2
6	transcriptional activator activity, RNA polymerase II transcription factor binding	GO:0001190	9.46	LMO2 NOTCH1
7	RNA polymerase II regulatory region sequence-specific DNA binding	GO:0000977	9.43	ETV6 LMO2 LYL1 PBX1 RUNX1 TAL2
8	DNA binding transcription factor activity	GO:0003700	9.32	AFF1 AFF4 ETV6 IKZF1 NOTCH1 OLIG2
9	protein binding	GO:0005515	10.21	ABL1 AFF1 AFF4 BAX BCL9 ETV6

Sources

Sources for Lymphoblastic Leukemia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ ExPASy

¹⁷ FDA Approved Drugs

¹⁸ FMA

¹⁹ GeneAnalytics

²⁰ GeneCards

²¹ GeneGo (Thomson Reuters)

²² GeneHancer via GeneCards

²³ GeneReviews

²⁴ Genetics Home Reference

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HGMD

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ MalaCards

³⁹ MedGen

⁴⁰ MedlinePlus

⁴¹ MeSH

⁴² MESH via Orphanet

⁴³ MGI

⁴⁴ NCBI Bookshelf

⁴⁵ NCI

⁴⁶ NCIt

⁴⁷ NDF-RT

⁴⁸ NIH Clinical Center

⁴⁹ NIH Rare Diseases

⁵⁰ NINDS

⁵¹ Novoseek

⁵² Novus Biologicals

⁵³ OMIM

⁵⁴ OMIM via Orphanet

⁵⁵ Orphanet

⁵⁶ PathCards

⁵⁷ PharmGKB

⁵⁸ PubMed

⁵⁹ PubMed Health

⁶⁰ QIAGEN

⁶¹ R&D Systems

⁶² Reactome

⁶³ Sino Biological

⁶⁴ SNOMED-CT

⁶⁵ SNOMED-CT via HPO

⁶⁶ SNOMED-CT via Orphanet

⁶⁷ TGDB

⁶⁸ Tocris

⁶⁹ UMLS

⁷⁰ UMLS via Orphanet

⁷¹ UniProtKB/Swiss-Prot

⁷² Wikipedia

Lymphoblastic Leukemia

Aliases & Classifications for Lymphoblastic Leukemia

MalaCards integrated aliases for Lymphoblastic Leukemia:

Classifications:

External Ids:

Summaries for Lymphoblastic Leukemia

Related Diseases for Lymphoblastic Leukemia

Diseases in the Lymphoblastic Leukemia family:

Diseases related to Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

Comorbidity relations with Lymphoblastic Leukemia via Phenotypic Disease Network (PDN):

Graphical network of the top 20 diseases related to Lymphoblastic Leukemia:

Symptoms & Phenotypes for Lymphoblastic Leukemia

UMLS symptoms related to Lymphoblastic Leukemia:

GenomeRNAi Phenotypes related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Lymphoblastic Leukemia:

Drugs & Therapeutics for Lymphoblastic Leukemia

FDA approved drugs:

Drugs for Lymphoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 69 / NDF-RT 47 :

Cochrane evidence based reviews: leukemia, lymphoid

Genetic Tests for Lymphoblastic Leukemia

Anatomical Context for Lymphoblastic Leukemia

MalaCards organs/tissues related to Lymphoblastic Leukemia:

Publications for Lymphoblastic Leukemia

Articles related to Lymphoblastic Leukemia:

Genes for Lymphoblastic Leukemia

Genes related to Lymphoblastic Leukemia (0 elite genes):

Variations for Lymphoblastic Leukemia

Expression for Lymphoblastic Leukemia

Pathways for Lymphoblastic Leukemia

Pathways related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

GO Terms for Lymphoblastic Leukemia

Cellular components related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

Biological processes related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

Molecular functions related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

Sources for Lymphoblastic Leukemia

Inferred drug relations via UMLS ⁶⁹ / NDF-RT ⁴⁷ :